Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (112)	9/25/2000 1:46:54 PM
From: keokalani'nui	Read Replies (1) of 138

Regarding today's PR, would anyone know if this is considered a generally accepted, and predictive, model of IBD? <<The preclinical study examined the effect of Androstenetriol (AET) (HE2200) in an experimental animal model of inflammatory bowel disease. In this model distal colitis was induced by intracolonic instillation of 2,4-dinitrobenzenesulfonic acid (DNBS). Animals received placebo, Sulfazalazine or HE2200. Sulfazalazine is currently a standard of care for treatment of ulcerative colitis. Animals were treated subcutaneously with HE2200 2 mg/day for 5 to 6 days. Sulfazalazine was administered orally for 7 days. The presence of diarrhea, intestinal adhesions, colonic ulcerations and colon-to-body weight ratios were recorded.>> Many thanks for any thoughts. --Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next